Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis Inc (PSNL) drives innovation in genome-guided medicine through advanced sequencing solutions and cancer immunotherapy research. This news hub provides investors and researchers with essential updates on the company’s scientific advancements and strategic developments.
Access authoritative reporting on PSNL’s financial results, clinical trial milestones, and technology partnerships. Our curated collection includes press releases on pharmacogenomics breakthroughs, regulatory filings, and collaborative research initiatives shaping personalized medicine.
Key coverage areas include precision oncology developments, genomic data platform enhancements, and biopharma collaborations. Stay informed about innovations in neoantigen discovery and therapeutic vaccine development through verified primary sources.
Bookmark this page for real-time updates on Personalis’ contributions to next-generation diagnostics and therapeutic solutions. Monitor critical updates through our organized repository of corporate communications and third-party analysis.
Personalis announced that two podium presentations and multiple posters featuring its NeXT Personal® ctDNA assay will be showcased at the 2024 ASCO Annual Meeting, set for May 31-June 4 in Chicago. The presentations include studies on ctDNA's role in breast cancer and immunotherapy biomarkers. Dr. Richard Chen highlighted the importance of their ultra-sensitive MRD test in early cancer detection. Key presentations will focus on ctDNA mutation tracking in early breast cancer (Abstract 1010) and ctDNA monitoring in metastatic pan-cancer with immune checkpoint inhibitors (Abstract 2510). Additional abstracts discuss ctDNA dynamics in gastroesophageal and colorectal cancers, as well as HER2+ breast cancer.
Personalis, a leader in advanced genomics for precision oncology, announced that its Compensation Committee has granted a non-qualified stock option to purchase 85,000 shares to its new Vice President, Customer Experience.
The grant, made on May 15, 2024, under the 2020 Inducement Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of $1.43 per share, matching the closing price on the grant date, and vests over four years.
Personalis, Inc. (Nasdaq: PSNL) reported financial results for Q1 2024, with revenue of $19.5 million, raising full-year revenue guidance due to increased pharma testing demand. They published validation for NeXT Personal MRD test, and launched NeXT Personal Dx clinical testing. The CEO highlighted a focus on the Win-in-MRD strategy and strong execution in Q1.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
